TRENDING :  Market Movers  |  Top 50   UHS (-8.2%)    UGAZ (-22.16%)    TVIX (7.92%)    TSLA (-2.95%)    SRPT (-2.05%)    SPY (-1.85%)    NBEV (0.85%)    MA (-1.83%)    HTGM (-1.97%)    GDX (-1.76%)    FB (-0.66%)    EWC (-1.17%)    CI (-3.11%)    CARA (-0.22%)    BTCUSD (%)    BHC (-3.3%)    ARGT (-1.53%)    AMZN (-4.01%)

Robert Gadimian

Joined: 8/5/2017
Education: Graduate
Trading Experience: 10-20 yrs
I have 20 years of experience in trading. I also have a extensive experience with drug development. I combine technical analysis, valuation of the company and the upcoming short term catalysts before trading. I will set a target price and very tight stop loss limits. I am an active trader and usually sell and jump in again in the same stock until it hits the target price. I like to take my profit after the little runs that the stocks have. It is a more conservative and profitable approach.

Learn More...


Total Recommendations


Open Recommendations

26.12 %

Success Rate


Total Services

My Services

Service NameAvg % Return
since Inception
% SuccessYTD ReturnAll Time ReturnRiskFees
Biotechnology-1.01 %-2/13426.12 %-6.11 %-13.66 %

Closed Recommendations

SymbolServiceTypeStrategy Created Closed% Return
AIMTBiotechnologyEquityBuy Long03/23/1804/03/18-5.04 %
IDRABiotechnologyEquityBuy Long01/26/1804/02/18-9.57 %
ADMSBiotechnologyEquityBuy Long03/23/1804/02/18-6.31 %
AVDLBiotechnologyEquityBuy Long03/23/1803/27/18-4.26 %
PRTKBiotechnologyEquityBuy Long03/23/1803/27/18-3.70 %
CDTXBiotechnologyEquityBuy Long03/23/1803/26/18-9.09 %
CPRXBiotechnologyEquityBuy Long03/23/1803/23/18-2.26 %
AKAOBiotechnologyEquityBuy Long01/02/1803/23/1819.40 %
ADXSBiotechnologyEquityBuy Long03/05/1803/12/1810.61 %
SGYPBiotechnologyEquityBuy Long12/13/1703/05/1811.11 %
LXRXBiotechnologyEquityBuy Long12/21/1702/09/18-13.29 %
NLNKBiotechnologyEquityBuy Long01/12/1802/06/18-6.54 %
PRTKBiotechnologyEquityBuy Long01/26/1802/02/18-4.15 %
TTPHBiotechnologyEquityBuy Long01/11/1802/01/18-15.38 %
QTNTBiotechnologyEquityBuy Long01/26/1801/31/18-8.26 %
ADMPBiotechnologyEquityBuy Long12/21/1701/29/18-14.61 %
ACRXBiotechnologyEquityBuy Long12/13/1701/26/180.00 %
RNNBiotechnologyEquityBuy Long10/25/1701/26/1822.53 %
SCYXBiotechnologyEquityBuy Long01/12/1801/16/18-2.63 %
KDMNBiotechnologyEquityBuy Long12/13/1701/12/188.38 %
TLGTBiotechnologyEquityBuy Long01/11/1801/12/18-4.95 %
TGTXBiotechnologyEquityBuy Long12/07/1701/11/1825.45 %
ARDMBiotechnologyEquityBuy Long01/04/1801/09/18-21.88 %
OVASBiotechnologyEquityBuy Long12/22/1701/04/18-7.59 %
EYEGBiotechnologyEquityBuy Long12/13/1701/03/18-9.92 %
ICPTBiotechnologyEquityBuy Long12/22/1701/02/18-7.58 %
AKTXBiotechnologyEquityBuy Long10/25/1712/22/174.05 %
RXIIBiotechnologyEquityBuy Long11/30/1712/21/17-15.91 %
KALABiotechnologyEquityBuy Long11/10/1712/13/17-7.81 %
EVOKBiotechnologyEquityBuy Long11/14/1712/13/17-10.39 %
ACRXBiotechnologyEquityBuy Long12/07/1712/12/17-9.09 %
LXRXBiotechnologyEquityBuy Long11/30/1712/12/17-4.11 %
OVASBiotechnologyEquityBuy Long11/30/1712/12/17-9.40 %
SGYPBiotechnologyEquityBuy Long11/15/1712/07/17-3.19 %
KDMNBiotechnologyEquityBuy Long11/03/1712/07/17-4.23 %
CNATBiotechnologyEquityBuy Long11/30/1712/06/17-6.92 %
ARLZBiotechnologyEquityBuy Long11/21/1711/30/17-3.27 %
ICPTBiotechnologyEquityBuy Long11/21/1711/28/17-3.77 %
TSROBiotechnologyEquityBuy Long11/15/1711/28/17-7.85 %
ZIOPBiotechnologyEquityBuy Long11/14/1711/21/170.71 %
PTCTBiotechnologyOptionsBuy Puts10/12/1711/17/17-96.43 %
PTCTBiotechnologyOptionsBuy Puts10/02/1711/17/17-96.15 %
ADMPBiotechnologyEquityBuy Long10/18/1711/15/17-10.00 %
ARDXBiotechnologyEquityBuy Long11/03/1711/14/17-8.62 %
TSROBiotechnologyEquityBuy Long11/14/1711/14/17-1.54 %
IOVABiotechnologyEquityBuy Long10/25/1711/14/179.79 %
RDHLBiotechnologyEquityBuy Long11/10/1711/14/17-4.49 %
TCONBiotechnologyEquityBuy Long11/03/1711/13/17-6.78 %
AKAOBiotechnologyEquityBuy Long11/08/1711/13/17-3.97 %
KERXBiotechnologyEquityBuy Long11/08/1711/10/17-4.59 %
ZIOPBiotechnologyEquityBuy Long11/08/1711/10/17-5.06 %
ATNMBiotechnologyEquityBuy Long10/11/1711/08/17-16.38 %
ICPTBiotechnologyEquityBuy Long09/29/1711/08/178.26 %
NVTABiotechnologyEquityBuy Long11/03/1711/07/17-3.73 %
TGTXBiotechnologyEquityBuy Long10/19/1711/03/173.90 %
MNOVBiotechnologyEquityBuy Long10/10/1710/27/177.61 %
KERXBiotechnologyEquityBuy Long10/26/1710/27/17-3.00 %
ARDXBiotechnologyEquityBuy Long10/18/1710/26/17-11.50 %
TSROBiotechnologyEquityBuy Long10/25/1710/26/17-0.35 %
AKAOBiotechnologyEquityBuy Long10/11/1710/25/17-4.90 %
TSROBiotechnologyEquityBuy Long10/19/1710/25/17-3.66 %
RNNBiotechnologyEquityBuy Long10/13/1710/25/17-13.88 %
LXRXBiotechnologyEquityBuy Long10/17/1710/24/17-4.34 %
ACRSBiotechnologyEquityBuy Long10/17/1710/23/17-1.75 %
TGTXBiotechnologyEquityBuy Long10/18/1710/18/17-3.66 %
SGYPBiotechnologyEquityBuy Long10/17/1710/18/17-5.19 %
TSROBiotechnologyEquityBuy Long10/12/1710/18/17-1.21 %
TCONBiotechnologyEquityBuy Long10/03/1710/17/17-13.04 %
QTNTBiotechnologyEquityBuy Long10/02/1710/17/17-6.86 %
ALDXBiotechnologyEquityBuy Long10/04/1710/16/17-7.38 %
ANTHBiotechnologyEquityBuy Long10/12/1710/16/17-6.98 %
IMDZBiotechnologyEquityBuy Long10/12/1710/16/17-2.73 %
AXSMBiotechnologyEquityBuy Long10/02/1710/13/17-7.08 %
ARDXBiotechnologyEquityBuy Long09/19/1710/12/1738.39 %
GBTBiotechnologyEquityBuy Long10/04/1710/12/175.65 %
ACRXBiotechnologyEquityBuy Long08/05/1710/12/17-13.79 %
AERIBiotechnologyEquityBuy Long10/02/1710/11/1720.97 %
TRVNBiotechnologyEquityBuy Long10/02/1710/10/17-6.84 %
AXONBiotechnologyEquityBuy Long10/03/1710/10/17-11.10 %
MTFBBiotechnologyEquityBuy Long09/19/1710/04/1733.49 %
HRTXBiotechnologyEquityBuy Long09/13/1710/03/1714.24 %
FLXNBiotechnologyEquityBuy Long09/29/1710/03/179.74 %
NUVABiotechnologyEquityBuy Long09/25/1710/02/170.11 %
ANTHBiotechnologyEquityBuy Long09/29/1709/29/17-4.11 %
ZGNXBiotechnologyEquityBuy Long09/05/1709/29/17134.40 %
RDHLBiotechnologyEquityBuy Long09/11/1709/28/1721.36 %
CATBBiotechnologyEquityBuy Long09/08/1709/28/1737.93 %
ICPTBiotechnologyEquityBuy Long09/26/1709/27/17-2.03 %
ICPTBiotechnologyEquityBuy Long09/22/1709/26/17-8.90 %
FLXNBiotechnologyEquityBuy Long09/08/1709/25/177.63 %
TRVNBiotechnologyEquityBuy Long09/20/1709/22/17-2.81 %
NBRVBiotechnologyEquityBuy Long09/20/1709/22/17-2.28 %
VSARBiotechnologyEquityBuy Long09/14/1709/20/1721.88 %
IDRABiotechnologyEquityBuy Long09/05/1709/19/1722.58 %
ACRSBiotechnologyEquityBuy Long09/11/1709/18/17-4.92 %
RXDXBiotechnologyEquityBuy Long09/13/1709/18/1715.38 %
NBRVBiotechnologyEquityBuy Long09/13/1709/15/17-7.06 %
VSARBiotechnologyEquityBuy Long09/13/1709/14/17-4.76 %
TGTXBiotechnologyEquityBuy Long09/07/1709/12/17-4.88 %
VSARBiotechnologyEquityBuy Long09/08/1709/12/17-5.18 %
HZNPBiotechnologyEquityBuy Long08/14/1709/11/1713.91 %
ADMPBiotechnologyEquityBuy Long09/08/1709/11/17-2.75 %
RDHLBiotechnologyEquityBuy Long09/08/1709/11/17-3.42 %
PETXBiotechnologyEquityBuy Long08/30/1709/08/1711.54 %
AUPHBiotechnologyEquityBuy Long09/06/1709/08/178.99 %
PCRXBiotechnologyEquityBuy Long08/30/1709/07/170.41 %
AXSMBiotechnologyEquityBuy Long08/30/1709/07/17-9.00 %
AXSMBiotechnologyEquityBuy Long08/30/1709/07/17-9.00 %
AXSMBiotechnologyEquityBuy Long08/30/1709/07/17-9.00 %
NVTABiotechnologyEquityBuy Long08/28/1709/06/17-2.44 %
AUPHBiotechnologyEquityBuy Long09/01/1709/05/17-2.48 %
LXRXBiotechnologyEquityBuy Long08/31/1709/05/17-2.32 %
FGENBiotechnologyEquityBuy Long08/23/1708/31/1713.99 %
INSMBiotechnologyEquityBuy Long08/17/1708/30/172.73 %
INSMBiotechnologyEquityBuy Long08/24/1708/30/17-2.28 %
PGNXBiotechnologyEquityBuy Long08/10/1708/30/1722.80 %
KMDABiotechnologyEquityBuy Long08/16/1708/30/172.41 %
NVTABiotechnologyEquityBuy Long08/22/1708/24/176.05 %
PCRXBiotechnologyEquityBuy Long08/22/1708/23/17-3.45 %
PCRXBiotechnologyEquityBuy Long08/14/1708/21/17-3.66 %
OMERBiotechnologyEquityBuy Long08/16/1708/21/17-5.60 %
ADMPBiotechnologyEquityBuy Long08/05/1708/17/170.00 %
KMDABiotechnologyEquityBuy Long08/14/1708/15/17-5.49 %
AXSMBiotechnologyEquityBuy Long08/05/1708/14/17-14.05 %
PCRXBiotechnologyEquityBuy Long08/10/1708/11/17-2.59 %
VSTMBiotechnologyEquityBuy Long08/09/1708/10/17-7.04 %
ARLZBiotechnologyEquityBuy Long08/05/1708/10/17-5.17 %
LXRXBiotechnologyEquityBuy Long08/09/1708/10/17-2.88 %
SRPTBiotechnologyEquityBuy Long08/05/1708/10/17-3.34 %
ABIOBiotechnologyEquityBuy Long08/09/1708/10/17-11.11 %
PGNXBiotechnologyEquityBuy Long08/05/1708/09/17-7.09 %
ADMPBiotechnologyEquityBuy Long08/07/1708/09/17-5.32 %
ABIOBiotechnologyEquityBuy Long08/05/1708/09/17-12.82 %
LXRXBiotechnologyEquityBuy Long08/05/1708/07/17-2.72 %


Canada Stocks Close Down More Than 30 Pts As Market Watchers Says Investors Are Putting Their Money In Cash Instead; Aphria and AltaGas In The News

Canada s main stock market the Toronto Stock Exchange on Thursday closed down 32 7 points at 14 750 35 above a day low 14 721 30 touched inside the last hour of trading but 120 points off an early day high as a plethora of issues cast a shadow over markets including uncertainty about

Visa & Mastercard: Strong Growth and Dividend Hike Opportunities?

Popular free stock trading app Robinhood announced today that it is launching checking and savings accounts These accounts will not only feature the fee free zero minimum standards that Robinhood users have come to expect but also 3 interest rates on deposits That return is roughly 30

What Investors Should Expect In 2019

With our current political climate the EU punishing Britain for Brexit tariffs trade wars the Fed raising rates record government deficits and whatever hysteria the media can create the crystal ball is full of clutter How should investors approach 2019 We

NVIDIA Should Pay a Bigger Dividend -- Here's Why

Graphics specialist NVIDIA NASDAQ NVDA first began paying a quarterly dividend back in November 2012 more than six years ago That initial dividend was just 0 075 per share but over time it has grown to 0 16 more than double where it started Although NVIDIA has done

Why Delta Stock Lost 5% Today

What happened Shares of Delta Air Lines NYSE DAL 160 were down 5 as of 2 40 p m EST on Thursday as investors reacted to an earnings warning 160 announced at Delta s investor day in New York In a press release preceding the actual conference Delta revealed that

Tesla Stock: Headed to $465?

Baird analyst Ben Kallo was already bullish on Tesla NASDAQ TSLA He had an outperform rating on the stock and a 411 price target But now he s even more optimistic reiterating his outperform rating and initiating a new higher 12 month price target To back up his bullish

SeaWorld Shareholders Can Exhale as the Stock Soars Higher

One of this year s biggest surprise winners is SeaWorld Entertainment NYSE SEAS Shares of the theme park operator have more than doubled in 2018 up 104 through Wednesday s close The good news keeps coming for the once out of favor entertainer as the Justice Department has

Express Scripts Announces 3-Year Agreement With Walmart

Leading pharmacy benefit manager Express Scripts Holding Company ESRX and retail giant 160 Walmart Inc WMT recently announced a three year agreement to deliver affordable prescription solutions to underinsured and uninsured Americans Financial terms of the deal have been kept under

Better Buy: Align Technology vs. Abiomed

Align Technology NASDAQ ALGN and Abiomed NASDAQ ABMD 160 have a lot of traits in common They are both medical device companies that dominate their respective niches They have each reached profitability and have been grand slam investments so far While both still

How Do You Monetize a Streaming Platform?

The cord cutting revolution kicked off in earnest when Netflix 160 announced its streaming service back in 2007 But another product announcement that year was similarly important Roku s NASDAQ ROKU 160 first Netflix player The device a box that could be connected

Apple Details Domestic Expansion Plans

Apple NASDAQ AAPL kicked off 2018 with a massive promise to invest 160 350 billion in the U S over the next five years However that headline figure was a little misleading as it included things like a mandatory 38 billion repatriation tax payment related to its

General Dynamics Wins $25M Deal to Support Submarine Platform

General Dynamics Corp s GD Electric Boat division recently secured a 24 8 million modification contract for providing engineering and technical design support services related to the undersea technology for current and future submarine platforms The deal has been awarded by The Naval

Nordson Corporation (NDSN) Q4 2018 Earnings Conference Call Transcript

Image source The Motley Fool Nordson Corporation NASDAQ NDSN Q4 2018 Earnings Conference Call Dec 13 2018 8 30 p m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator

Red Hat (RHT) Set to Report Q3 Earnings: What's in Store?

Red Hat Inc RHT is set to report third quarter fiscal 2019 results on Dec 17 We note that on average the company has delivered a positive earnings surprise of 7 2 in the trailing four quarters In the last reported quarter Red Hat delivered positive earnings surprise of 4

Ciena Corporation (CIEN) Q4 2018 Earnings Conference Call Transcript

Image source The Motley Fool Ciena Corporation NYSE CIEN Q4 2018 Earnings Conference Call Dec 13 2018 8 30 a m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator
© StockHoot LLC 2018. Made in Chicago.

Terms  | Privacy Policy  | Contact Us  | Feedback 

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.

Cryptocurrency data provided by CryptoCompare